74P - Clinical translation of serum microRNA 21 as a potential prognostic marker in breast cancer patients and predictive marker of radiotherapy

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Breast Cancer, Early Stage
Translational Research
Surgical Oncology
Presenter Dariush Moslemi
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors D. Moslemi1, H. Parsian2, M. Halimi2
  • 1Radiation Oncology, Babol University of Medical Sciences (BUMS), 47176-47745 - Babol/IR
  • 2Biochemistry, Babol University of Medical Sciences (BUMS), 47176-47745 - Babol/IR



With regard to the variability in clinical progression of breast cancer, the identification of markers capable of predicting tumor behavior and its therapeutic response would be of paramount importance. The present study assessed the potential of circulating miR-21 in functioning as a prognostic marker and predictive marker of radiotherapy in breast cancer patients.


Patients We investigated serum level of miR-21 in a cohort of 40 breast cancer patients before and after radiotherapy in addition to 20 healthy age- and gender-matched volunteers. Moreover, the prognostic and predictive value of miR-21 was determined through exploring the correlation between expression levels of miR-21 before and after radiotherapy and local recurrence, progression-free survival (PFS) and overall survival (OS).


The results showed a significant increase in serum miR-21 level after radiotherapy (P 


Although the precise molecular mechanism of serum miR-21 increase following radiotherapy would require further clarification, the finding indicated that miR-21 might be a good candidate as a molecular prognostic marker, and predictive marker of radiotherapy in breast cancer.

Clinical trial indentification

Legal entity responsible for the study



Babol university of medical sciences


All authors have declared no conflicts of interest.